BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29749339)

  • 1. Intestinal perforation after regorafenib usage.
    Sarıcı B; Karakaş S; Uylas U; Aktaş A; Dikilitaş M; Kayaalp C
    Turk J Gastroenterol; 2018 Mar; 29(2):245-247. PubMed ID: 29749339
    [No Abstract]   [Full Text] [Related]  

  • 2. Regorafenib use as a possible cause of intestinal perforation.
    Adenis A; Kotecki N; Decanter G; Clisant S; Penel N
    Acta Oncol; 2013 Nov; 52(8):1789-90. PubMed ID: 24024697
    [No Abstract]   [Full Text] [Related]  

  • 3. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
    Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
    J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal Perforation in a Patient with Colon Cancer during Treatment with Regorafenib: A Case Report and Review of the Literature.
    Ouchi R; Okada K; Usui K; Kurata N; Suzuki S; Nagao M; Watanabe Y; Koyama K
    Tohoku J Exp Med; 2021 Jul; 254(3):207-211. PubMed ID: 34321384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
    Park SG; Chung CH; Park CY
    Tumori; 2011; 97(6):794-9. PubMed ID: 22322848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
    Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
    [No Abstract]   [Full Text] [Related]  

  • 7. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
    Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib-Associated Vulvar Psoriasiform Skin Reaction: Case of the Month from the ISSVD Case Consultation Committee.
    Bourne EL; Day T; Scurry J
    J Low Genit Tract Dis; 2016 Jul; 20(3):e44-5. PubMed ID: 27195780
    [No Abstract]   [Full Text] [Related]  

  • 9. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
    Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib-Associated Fatigue: A Systematic Review and Meta-analysis.
    Invally M; Kanukula R; Salam MA; Shruthi G
    Am J Ther; 2018; 25(6):e715-e717. PubMed ID: 29465445
    [No Abstract]   [Full Text] [Related]  

  • 11. Ileal perforation following cetuximab and FOLFIRI chemotherapy in a patient with ascending colon cancer with peritoneal carcinomatosis.
    Kim YW
    J BUON; 2017; 22(3):804-805. PubMed ID: 28730797
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen.
    García-Gutiérrez I; Acevedo M; Tornero P; Matilla A; Márquez L; Sánchez-Herrero A; Prieto-García A
    J Investig Allergol Clin Immunol; 2019 Aug; 29(4):300-302. PubMed ID: 31478526
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
    Frieling T; Heise J; Wassilew SW
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):e1-2, 1464-6. PubMed ID: 19572243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib- associated panniculitis.
    Chockalingam R; Aung P; Patel AB
    Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
    Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
    Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib for treatment of hepatocellular carcinoma.
    Sherman M
    Hepatology; 2018 Mar; 67(3):1162-1165. PubMed ID: 29059458
    [No Abstract]   [Full Text] [Related]  

  • 17. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
    Grothey A
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
    [No Abstract]   [Full Text] [Related]  

  • 18. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
    Draper A
    Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
    [No Abstract]   [Full Text] [Related]  

  • 19. Regorafenib: start low and go slow.
    Tabchi S; Ghosn M
    Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular toxicity of regorafenib for heavily-treated osteosarcoma.
    Saito Y; Makimoto A; Miura M; Yuza Y
    Pediatr Int; 2021 Jul; 63(7):857-859. PubMed ID: 33277804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.